Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Glukosemønster hos infertile kvinder, der modtager assisteret reproduktion ved hjælp af kontinuerlig glukoseovervågning

17. november 2026 opdateret af: Jian Zhou, Shanghai 6th People's Hospital

Glukosemønster hos infertile kvinder, der modtager assisteret reproduktion: En prospektiv undersøgelse ved hjælp af kontinuerlig glukoseovervågning

No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200233
        • Shanghai Sixth People's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 40 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Informed consent and voluntary participation in this study;
  2. Age ≥ 18 years and ≤40 years old;
  3. Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
  4. The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.

Exclusion Criteria:

  1. Recent infections (excluding viral infections of the reproductive system such as HPV);
  2. Recent glucocorticoid treatment or chemotherapy;
  3. Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
  4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: wearing continuous glucose monitorings

Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.

Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.

In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean sensor glucose (MSG)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Mean of daily continuous 24-h blood glucose

Through study completion (during assisted reproductive treatment period,about 2 months)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
time in tight range(3.9~7.8mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Time below range (<3.9mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM.

Through study completion (during assisted reproductive treatment period,about 2 months)
Time above range (>7.8mmol/L, %)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Coefficient of variation (CV)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation divided by mean glucose level measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Standard deviation (SD)
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation of blood glucose measurements during CGM

Through study completion (during assisted reproductive treatment period,about 2 months)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of oocytes retrieved
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of oocytes obtained under ultrasound guidance

Through study completion (during assisted reproductive treatment period,about 2 months)
Oocyte retrieval rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles

Through study completion (during assisted reproductive treatment period,about 2 months)
Number of MII oocytes
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of metaphase II oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of MII oocytes
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of high-quality embryos
Tidsramme: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of Day 2 and Day 3 embryos with high score or grade

Through study completion (during assisted reproductive treatment period,about 2 months)
Biochemical pregnancy rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat.

Through study completion (during assisted reproductive treatment period,about 6 months)
Clinical pregnancy rate
Tidsramme: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy

Through study completion (during assisted reproductive treatment period,about 6 months)
Miscarriage rate
Tidsramme: Through study completion, about 1 year

The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy

Through study completion, about 1 year
Live Birth Rate
Tidsramme: Through study completion, 18 months

The proportion of successful deliveries resulting in a live-born infant.

Through study completion, 18 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. marts 2025

Primær færdiggørelse (Faktiske)

30. juni 2026

Studieafslutning (Anslået)

30. april 2027

Datoer for studieregistrering

Først indsendt

3. marts 2025

Først indsendt, der opfyldte QC-kriterier

6. marts 2025

Først opslået (Faktiske)

7. marts 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner